Volume 32, Nº 5, Setembro e Outubro 2019
DOI: http://www.dx.doi.org/10.5935/2359-4802.20190041
EDITORIAL
Rheumatic Heart Disease - How are We in 2019, Have We Evolved?
Andressa Mussi Soares
![](images/rheumatic-heart-disease-how-are-we-in-2019-have-we-evolved.jpg)
Acute rheumatic fever (ARF) is the result of na autoimmune response to pharyngitis caused by infection with the sole member of the group A Streptococcus (GAS), Streptococcus pyogenes. ARF leads to a condition characterized by various combinations of joint pain and swelling, cardiac-valve regurgitation with the potential for secondary heart failure, chorea, skin and subcutaneous manifestations, and fever.
Rheumatic heart disease (RHD) is a disease of poverty that affects children and working-age adults. The global economic impact of early death from RHD is still very high. In Brazil, the average cost of RHD-related damage is around 89 million Brazilian reals (close to US$ 28 million) a year. Information from the Brazilian Unified National Health System database (DATASUS) indicates a cardiac mortality rate of about 7.9% from chronic rheumatic fever (RF).1
Keywords: Rheumatic heart disease; chronic valvular heart disease; control programs; corticosteroids; echocardiography.